Inflammation-sensitive proteins and risk of atrial fibrillation: A population-based cohort study

European Journal of Epidemiology

Volumn 26, Issue 6, 2011, Pages 449-455

  Adamsson Eryd, Samuel ^a   Smith, J Gustav ^b   Melander, Olle ^a   Hedblad, Bo ^a   Engström, Gunnar ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Atrial fibrillation; Epidemiology; Inflammation

Indexed keywords

ALPHA 1 ANTITRYPSIN; CERULOPLASMIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; FIBRINOGEN; HAPTOGLOBIN; OROSOMUCOID;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HOSPITALIZATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR;

ACUTE-PHASE PROTEINS; ALPHA 1-ANTITRYPSIN; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CERULOPLASMIN; COHORT STUDIES; COMPLEMENT C3; COMPLEMENT C4; FIBRINOGEN; FOLLOW-UP STUDIES; HAPTOGLOBINS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; OROSOMUCOID; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SWEDEN;

EID: 79959762923     PISSN: 03932990     EISSN: 15737284     Source Type: Journal    
DOI: 10.1007/s10654-011-9565-6     Document Type: Article

References (41)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anti coagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001;285(18):2370-5. (Pubitemid 32424106)
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-25.
3. Wolf PA, Benjamin EJ, Belanger AJ, Kannel WB, Levy D, D'Agostino RB. Secular trends in the prevalence of atrial fibrillation: the Framingham study. Am Heart J. 1996;131(4):790-5. (Pubitemid 26116354)
4. Kannel WB, Benjamin EJ. Current perceptions of the epidemiology of atrial fibrillation. Cardiol Clin. 2009;27(1):13-24.
5. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. 2004;110(9):1042-6. (Pubitemid 39319000)
6. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham heart study. JAMA. 1994;271(11):840-4.
7. Psaty BM, Manolio TA, Kuller LH, Kronmal RA, Cushman M, Fried LP, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997;96(7):2455-61. (Pubitemid 27425856)
8. Smith JG, Platonov PG, Hedblad B, Engstrom G, Melander O. Atrial fibrillation in the Malmo diet and cancer study: a study of occurrence, risk factors and diagnostic validity. Eur J Epidemiol. 2010;25(2):95-102.
9. Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L, Lindgarde F. Effects of cholesterol and inflammation-sensitive plasma proteins on incidence of myocardial infarction and stroke in men. Circulation. 2002;105(22):2632-7. (Pubitemid 34596040)
10. Koenig W. Fibrin(ogen) in cardiovascular disease: an update. Thromb Haemost. 2003;89(4):601-9. (Pubitemid 36456957)
11. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14):1387-97. (Pubitemid 38419992)
12. Lowe GD. Circulating inflammatory markers and risks of cardiovascular and non-cardiovascular disease. J Thromb Haemost. 2005;3(8):1618-27. (Pubitemid 41716547)
13. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294(14):1799-809. (Pubitemid 41434626)
14. Issac TT, Dokainish H, Lakkis NM. Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data. J Am Coll Cardiol. 2007;50(21): 2021-8. (Pubitemid 350087568)
15. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation. 2003;108(24):3006-10. (Pubitemid 37553570)
16. Schnabel RB, Larson MG, Yamamoto JF, Sullivan LM, Pencina MJ, Meigs JB, et al. Relations of biomarkers of distinct pathophysiological pathways and atrial fibrillation incidence in the community. Circulation. 2010;121(2):200-7.
17. Dernellis J, Panaretou M. Effects of C-reactive protein and the third and fourth components of complement (C3 and C4) on incidence of atrial fibrillation. Am J Cardiol. 2006;97(2):245-8. (Pubitemid 43139244)
18. Schnabel RB, Larson MG, Yamamoto JF, Kathiresan S, Rong J, Levy D, et al. Relation of multiple inflammatory biomarkers to incident atrial fibrillation. Am J Cardiol. 2009;104(1):92-6.
19. Engstrom G, Hedblad B, Tyden P, Lindgarde F. Inflammation-sensitive plasma proteins are associated with increased incidence of heart failure: a population-based cohort study. Atherosclerosis. 2009;202(2):617-22.
20. Engstrom G, Stavenow L, Hedblad B, Lind P, Eriksson KF, Janzon L, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: a population-based study. Diabetes. 2003;52(2):442-7. (Pubitemid 36173201)
21. Kristenson H, Trell E. Indicators of alcohol consumption: comparisons between a questionnaire (Mm-MAST), interviews and serum gamma-glutamyl transferase (GGT) in a health survey of middle-aged males. Br J Addict. 1982;77(3):297-304. (Pubitemid 12031894)
22. Laurell CB. Electroimmuno assay. Scand J Clin Lab Invest Suppl. 1972;124:21-37.
23. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F. Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes. 2005;54(2):570-5.
24. Smith JG, Newton-Cheh C, Almgren P, Struck J, Morgenthaler NG, Bergmann A, et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J Am Coll Cardiol. 2010;56(21):1712-9.
25. Waldo AL, Feld GK. Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications. J Am Coll Cardiol. 2008;51(8):779-86. (Pubitemid 351253742)
26. Marott SC, Nordestgaard BG, Zacho J, Friberg J, Jensen GB, Tybjaerg-Hansen A, et al. Does elevated C-reactive protein increase atrial fibrillation risk? A Mendelian randomization of 47,000 individuals from the general population. J Am Coll Cardiol. 2010;56(10):789-95.
27. Ehrenwald E, Chisolm GM, Fox PL. Intact human ceruloplasmin oxidatively modifies low density lipoprotein. J Clin Invest. 1994;93(4):1493-501. (Pubitemid 24116385)
28. Ryden L. In: Lontie R, editor. Copper proteins and copper enzymes. Boca Raton, Florida: CRC Press; 1984. pp. 37-100.
29. Turnlund JR, Jacob RA, Keen CL, Strain JJ, Kelley DS, Domek JM, et al. Long-term high copper intake: effects on indexes of copper status, antioxidant status, and immune function in young men. Am J Clin Nutr. 2004;79(6):1037-44. (Pubitemid 41095956)
30. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation. 2001;104(2):174-80. (Pubitemid 32655834)
31. Ozaydin M, Peker O, Erdogan D, Kapan S, Turker Y, Varol E, et al. N-acetylcysteine for the prevention of postoperative atrial fibrillation: a prospective, randomized, placebo-controlled pilot study. Eur Heart J. 2008;29(5):625-31.
32. Neuman RB, Bloom HL, Shukrullah I, Darrow LA, Kleinbaum D, Jones DP, et al. Oxidative stress markers are associated with persistent atrial fibrillation. Clin Chem. 2007;53(9):1652-7. (Pubitemid 47340062)
33. Ellinor PT, Low A, Patton KK, Shea MA, MacRae CA. C-reactive protein in lone atrial fibrillation. Am J Cardiol. 2006;97(9): 1346-50.
34. Pan M, Zhu JH, Jiang WP, Liu ZH, Li HM, Yu XH, et al. Inflammation: a possible pathogenic link to atrial fibrillation. Med Hypotheses. 2006;67(6):1305-7. (Pubitemid 44442636)
35. Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96(4):1180-4. (Pubitemid 27344221)
36. Nakamura Y, Nakamura K, Fukushima-Kusano K, Ohta K, Matsubara H, Hamuro T, et al. Tissue factor expression in atrial endothelia associated with nonvalvular atrial fibrillation: possible involvement in intracardiac thrombogenesis. Thromb Res. 2003;111(3):137-42. (Pubitemid 37540411)
37. Conen D, Osswald S, Albert CM. Epidemiology of atrial fibrillation. Swiss Med Wkly. 2009;139(25-26):346-52.
38. Engstrom G, Janzon L, Berglund G, Lind P, Stavenow L, Hedblad B, et al. Blood pressure increase and incidence of hypertension in relation to inflammation-sensitive plasma proteins. Arterioscler Thromb Vasc Biol. 2002;22(12):2054-8. (Pubitemid 36025214)
39. Engstrom G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgarde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes. 2003;52(8):2097-101. (Pubitemid 36919804)
40. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
41. Wood AM, White I, Thompson SG, Lewington S, Danesh J. Regression dilution methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 adults in 15 prospective studies. Int J Epidemiol. 2006;35(6):1570-8.